Palette Life Sciences today announced the launch of a new podcast series, The PedSpace, created specifically for and presented by pediatric urology healthcare professionals. The podcast features valuable information and insights, as part of Palette Life Sciences’ new Deflux Learning Center, a platform that provides information, education and training for pediatric urologists and their peers.
“As a pediatric urologist, I’m delighted to be participating in this new series developed specifically by and for my peers and I hope they will find it a valuable and interesting new resource.” – Dr. Aaron Martin, Board-certified Pediatric Urologist of Children’s Hospital New Orleans
SANTA BARBARA, CALIF., AND STOCKHOLM, SWEDEN (PRWEB) JULY 07, 2020
Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the launch of a new podcast series, The PedSpace, created specifically for and presented by pediatric urology healthcare professionals. The podcast series is a featured resource in Palette’s new Deflux Learning Center, an online platform that provides information, education and training globally for pediatric urologists and their peers who treat vesicoureteral reflux (VUR) and other pediatric urology conditions. VUR, sometimes referred to as urinary or bladder reflux, is a serious pediatric urinary condition in which urine flows from the bladder through one or both ureters toward the kidneys.
The PedSpace podcast series features physicians discussing the field of pediatric urology, compelling VUR-related information, Deflux as a treatment option, broader topics such as telemedicine and more. In the first episode, “The Art of a Telemedicine Visit,” Dr. Aaron Martin, Board-certified Pediatric Urologist at Children’s Hospital New Orleans discusses best practices for virtual patient care. In the second episode, “Telemedicine and VUR,” Dr. Martin discusses telemedicine in the context of VUR. In the third episode, “Improving the VUR Grading System,” Dr. Christopher Cooper, Board-Certified Pediatric Urologist at Stead Family Children’s Hospital in Iowa, discusses the limitations of the current VUR grading system, asserting that not all VUR is created equal, and asking if the old method of grading is obsolete.
“As a pediatric urologist, I’m delighted to be participating in this new series developed specifically by and for my peers, and I hope they will find it a valuable and interesting new resource,” said Dr. Aaron Martin, Board-certified Pediatric Urologist of Children’s Hospital New Orleans.
“Palette Life Sciences is dedicated to supporting learning and collaboration among pediatric urologists. Through the launch of The PedSpace podcast series and our Deflux Learning Center, we hope to play an important role in improving patient outcomes,” said Rich Low, head of marketing, Palette Life Sciences. “These are just two examples of how we are making significant new investments in physician education and training, fostering peer-to-peer collaboration for the ultimate benefit of our young patients and their caregivers.”
In addition to The PedSpace podcast series, the Deflux Learning Center contains comprehensive VUR and Deflux-related information, education, training, tools and resources to support healthcare professionals who treat VUR. The PedSpace can also be subscribed to via Apple, Google, or Spotify podcasts.
Deflux is a minimally invasive, outpatient treatment that has been proven safe and effective in children with vesicoureteral reflux (VUR). VUR is a serious pediatric urinary condition in which urine refluxes from the bladder through one or both ureters toward the kidneys, due to an abnormality at the junction of the ureter and the bladder. Deflux is an injectable gel bulking agent made from two tissue-friendly polysaccharides; Non-Animal Stabilized Hyaluronic Acid (NASHA®) and dextranomer (Dx) microspheres. The product is administered via injection around the ureteral opening to prevent urine reflux. Deflux is indicated in the United States for children with VUR grades II-IV, and is indicated outside of the United States for all grades of VUR. For more information, visit https://deflux.com.
About Palette Life Sciences AB
Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences’ products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company’s portfolio of available products includes Deflux®, Solesta® and Barrigel®. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, and Dallas, Texas. Learn more at https://www.palettelifesciences.com.